AMGN stock surged to a new annual high within a broader Nasdaq 100 rally, drawing fresh interest from Indian investors seeking healthcare exposure. AMGN last traded near $377, below the $391.29 year high, after a strong quarter and upbeat analyst revisions. Sentiment also benefits from progress on the MariTide Phase 3 obesity program and a new $4 billion long-dated bond issue to fund growth. We break down price levels, fundamentals, catalysts, and India-specific considerations to help you decide your next step.

Nasdaq 100 tailwind and today’s price action

AMGN stock has outperformed as investors rotated into profitable large-cap biotech while the Nasdaq 100 gained 21.02% over one year. Shares trade above the 50-day ($349.01) and 200-day ($310.31) averages, signaling trend strength. ADX at 29.84 confirms momentum. The annual high stands at $391.29, achieved during the Nasdaq 100 rally source.

Price sits near $377.00 with a day range of $372.71-$381.74. RSI at 56.84 is constructive, while ATR at 9.23 implies wider swings. The Bollinger middle band at $373.98 is first support; upper band at $395.49 lines up above the $391.29 high as resistance. Traders may watch $381.74, then $391-$395, for breakouts on rising volume.

Fundamentals, valuation, and Street stance

AMGN stock trades at a TTM P/E of 26.46 on EPS of $14.25. Margins remain strong: gross 70.49%, operating 27.99%, and net 20.97%. Dividend yield is 2.55% on $9.66 TTM dividends with a 66% payout ratio. Year to date, shares are up 15.07%. The analyst mix shows 12 Buy, 6 Hold, and 1 Sell ratings, indicating a positive skew.

Leverage is notable: debt-to-equity 6.31, net debt-to-EBITDA 2.43, and interest coverage 3.72. Current ratio is 1.14. Management raised $4 billion in long-dated bonds to support pipeline and growth, extending maturities and adding flexibility source. Stock Grade is B+ with a BUY suggestion, aligning with improving sentiment.

Pipeline watch: MariTide Phase 3 and near-term catalysts

Investors are focused on MariTide Phase 3 in obesity, a large market with strong demand signals. Clear readouts and safety consistency would be key supports for AMGN stock. While timelines were not disclosed here, progress updates, enrollment status, and comparator data versus leading GLP-1 agents will drive valuation and options pricing ahead of results.

The next earnings report is due on 30 April 2026. We will monitor revenue mix shifts, margin guidance, and R&D cadence tied to MariTide Phase 3. Watch any regulatory interactions, manufacturing scale-up commentary, and payer access plans. Technical confirmation above $391.29 with strong breadth could add momentum into catalyst windows.

What this means for Indian investors

Indian investors can gain exposure to AMGN stock via global brokers or NSE IFSC platforms that allow USD trading. Returns in INR will depend on USDINR moves, so currency adds another risk layer. Factor in brokerage, custody, and remittance charges under LRS. Tax treatment follows capital gains rules; consult a professional for individual rates and holding period rules.

Biotech carry binary pipeline risks alongside strong cash generation. Use measured position sizes and diversify across sectors. For traders, ATR of 9.23 suggests setting wider stops and smaller sizes. Investors can add on pullbacks toward the 50-day average if the thesis holds. Reassess on leverage trends, trial milestones, and post-earnings guidance.

Final Thoughts

AMGN stock sits in a constructive uptrend after printing a $391.29 annual high, backed by durable margins, a 2.55% dividend yield, and supportive Street sentiment. Technicals point to clear levels: support near the 50-day average and $374, and resistance at $381 and $391-$395. Fundamentally, investors should balance strong cash generation with higher leverage and execution risk on MariTide Phase 3. With the next earnings on 30 April 2026, we favor a disciplined plan: build positions on weakness, size for currency and trial risk, and review outcomes against margin guidance and pipeline updates. For India-based investors, consider USD exposure, costs, and taxes before acting.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes.  Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.